Translational research (TR) results from pointbreak: A randomized, open-label, phase III study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance pem+bev (Pem Arm) versus paclitaxel (Pac)+cb+bev followed by maintenance bev (Pac Arm) in patients (pts) with stage IIIB or IV nonsquamous non-small cell lung cancer (ns-NSCLC).
Edward B. Garon
Research Funding - Lilly
Jyoti D. Patel
No relevant relationships to disclose
Scott Myrand
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Tuan Nguyen
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Craig H. Reynolds
Consultant or Advisory Role - Genentech; Lilly
Honoraria - Genentech; Lilly
Research Funding - Lilly
David R. Spigel
Consultant or Advisory Role - Lilly
Robert C. Hermann
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Lilly; Roche/Genentech
Jingyi Liu
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Susan C. Guba
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Ramaswamy Govindan
Consultant or Advisory Role - Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; Merck
Honoraria - Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; Merck
Mark A. Socinski
Honoraria - Lilly
Research Funding - Lilly
Philip Bonomi
Consultant or Advisory Role - ImClone Systems; Lilly
Research Funding - ImClone Systems; Lilly